A detailed history of Israel Englander (Millennium Management LLC) transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 10,547 shares of ATHA stock, worth $7,382. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,547
Previous 141,661 92.55%
Holding current value
$7,382
Previous $388,000 93.04%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.92 - $2.71 $251,738 - $355,318
-131,114 Reduced 92.55%
10,547 $27,000
Q1 2024

May 15, 2024

SELL
$2.24 - $4.15 $703,799 - $1.3 Million
-314,196 Reduced 68.92%
141,661 $388,000
Q4 2023

Feb 14, 2024

SELL
$1.39 - $2.46 $484,508 - $857,474
-348,567 Reduced 43.33%
455,857 $1.11 Million
Q2 2023

Aug 14, 2023

BUY
$2.36 - $3.59 $643,059 - $978,213
272,483 Added 51.22%
804,424 $2.37 Million
Q1 2023

May 15, 2023

BUY
$2.26 - $4.22 $1.12 Million - $2.09 Million
495,515 Added 1360.33%
531,941 $1.33 Million
Q4 2022

Feb 14, 2023

BUY
$2.76 - $3.71 $21,842 - $29,360
7,914 Added 27.76%
36,426 $115,000
Q3 2022

Nov 14, 2022

SELL
$2.93 - $3.96 $16,982 - $22,952
-5,796 Reduced 16.89%
28,512 $85,000
Q2 2022

Aug 15, 2022

BUY
$2.74 - $13.43 $94,003 - $460,756
34,308 New
34,308 $105,000
Q3 2021

Nov 15, 2021

SELL
$9.15 - $11.09 $474,363 - $574,938
-51,843 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$10.24 - $20.87 $4.7 Million - $9.57 Million
-458,552 Reduced 89.84%
51,843 $531,000
Q1 2021

May 17, 2021

BUY
$16.9 - $29.77 $6.89 Million - $12.1 Million
407,549 Added 396.27%
510,395 $9.39 Million
Q4 2020

Feb 16, 2021

SELL
$16.48 - $34.3 $2.02 Million - $4.21 Million
-122,646 Reduced 54.39%
102,846 $3.52 Million
Q3 2020

Nov 16, 2020

BUY
$16.02 - $18.46 $3.61 Million - $4.16 Million
225,492 New
225,492 $4.16 Million

Others Institutions Holding ATHA

About Athira Pharma, Inc.


  • Ticker ATHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,817,700
  • Market Cap $26.5M
  • Description
  • Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...
More about ATHA
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.